Showing results (1021-1030 of 1,351) with videos related to
Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patientsXuejun Chen, Jack G Shi, Thomas Emm, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics and comparative bioavailability of domperidone suspension and tablet formulations in healthy adult subjectsSally A Helmy, Heba M El BedaiwyClinical Pharmacology in Drug Development|April 30, 2016
Safety, tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate, a novel inhaled corticosteroid, in children aged 5-11 years with persistent asthma: A randomized trialAmanda Oliver, Ann Allen, Sandi VanBuren, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patientsHuifen Faye Wang, Feng Qiu, Xiongfe Wu, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13-17 years with attention-deficit/hyperactivity disorderPatrick Martin, Lawrence Satin, Bradley D Vince, et al.Clinical Pharmacology in Drug Development|April 30, 2016
A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose studyDavid H Salinger, Christopher J Endres, David A Martin, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitorJean-Francois Marier, Mohamad-Samer Mouksassi, Nathalie H Gosselin, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteersVirginia Norris, Claire Ambery, Trevor RileyClinical Pharmacology in Drug Development|April 30, 2016
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjectsChao Xu, Chao Han, Joseph Marini, et al.Pageof 136